TIDMNSCI
NetScientific PLC
13 April 2018
NetScientific plc
("NetScientific" or the "Company" or the "Group")
Vortex Biosciences to Present Compelling Liquid Biopsy Data in
Collaboration with Stanford University School of Medicine and UCLA
at AACR 2018
Data demonstrates the use of circulating tumor cells for
identifying clinical biomarkers, such as EGFR mutations and PD-L1
expression, in patients with Non-Small Cell Lung Cancer (NSCLC)
London, UK - 16 April 2018 - NetScientific plc ("NetScientific",
AIM:NSCI), the transatlantic healthcare IP commercialisation group,
announces that its US-based portfolio company, Vortex BioSciences,
a leading liquid biopsy company, is presenting compelling new data
at the American Association for Cancer Research (AACR) Annual
Meeting in Chicago 14 - 18 April, 2018. These studies support the
use of Vortex's non-invasive technology in the characterisation of
circulating tumour cells (CTCs) for important clinical biomarkers,
namely EGFR and PD-L1, which play a pivotal role in the development
and progression of certain cancer in patients with non-small cell
lung cancer (NSCLC).
Commenting on the news, Francois Martelet, Chairman of Vortex
BioSciences Inc. and CEO of NetScientific said: "The studies
presented underscore the potential use of Vortex's technology in
the diagnosis and treatment of cancer patients. It is paramount to
understand which patients are likely to exhibit a superior response
to targeted therapies in order to determine the best treatment
algorithm, as well as to contain healthcare expenditure. We firmly
believe that Vortex's technology can play an instrumental role in
this."
# # #
For more information, please contact:
NetScientific Tel: +44 (0)20 3514 1800
François R. Martelet,
M.D., CEO
Ian Postlethwaite,
CFO
Consilium Strategic Tel: +44 (0)20 3709 5700
Communications netscientific@consilium-comms.com
Mary-Jane Elliott /
Jessica Hodgson /
Chris Welsh / Laura
Thornton
Stifel Nicolaus Europe
Limited (NOMAD and Broker) Tel: +44 (0) 20 7710 7600
Jonathan Senior / David
Arch / Ben Maddison
Tel: +1 (0) 415 823 7649
Vortex Biosciences steve@vortexbiosciences.com
Steve Crouse
About NetScientific
NetScientific is a transatlantic healthcare technology group
with an investment strategy focused on sourcing, funding and
commercialising technologies that significantly improve the health
and well-being of people with chronic diseases. For more
information, please visit the website at www.netscientific.net
MEDIA CONTACT
Steve Crouse
415-823-7649
steve@vortexbiosciences.com
Vortex Biosciences to Present Compelling Liquid Biopsy Data in
Collaboration with Stanford University School of Medicine and UCLA
at AACR 2018
Data demonstrates the use of the VTX-1 Liquid Biopsy System in
isolating and analyzing circulating tumor cells for clinical
biomarkers
MENLO PARK, CA, 14 April, 2018. Vortex Biosciences, a leader in
solutions for liquid biopsies, will present two posters at the
American Association for Cancer Research (AACR) Annual Meeting 2018
(April 14-18, Chicago, IL). Data presented at AACR will demonstrate
the ability of the VTX-1 Liquid Biopsy System to rapidly collect
highly enriched populations of circulating tumor cells (CTCs) for
the identification of EGFR mutations and PD-L1 expression.
"We have been excited about how well the CTCs are isolated from
a patient's blood using the VTX-1 system," said Elodie Sollier,
Chief Scientific Officer at Vortex Biosciences. "We are now seeing
the potential of utilizing CTCs for clinical applications as we
develop workflows for characterizing the cancer biology of these
cells."
Poster presentations:
Title: EGFR mutational detection in vortex-enriched CTCs, ctDNA,
and comparison to tumor tissue in non-small cell lung cancer
(NSCLC) patients
Date and time: April 16, 2018, 8:00 AM - 12:00 PM
Location: Section 26, poster 25
Summary: This study shows the clinical potential of identifying
actionable EGFR mutations in both the ctDNA and the CTCs from a
single blood collection tube in NSCLC patients. A workflow is
presented that allows for the collection of plasma prior to
isolation of the CTCs on the VTX-1 system. The DNA is then
extracted from both the plasma and the CTCs to perform EGFR
mutation detection in both ctDNA and CTCs. 20 blood samples were
studied from 15 NSCLC patients. Combining these sample types
resulted in identifying mutations that would have been missed if
only the ctDNA or CTCs were examined alone. The results are
compared to the EGFR mutations found in the patient's tumor tissue.
By looking at CTCs and ctDNA as complementary to each other, a
better mutation profile of the patient can be understood.
List of presenters/authors available online here.
Title: A workflow to evaluate PD-L1 protein expression on
circulating tumor cells (CTCs) from non-small cell lung cancer
(NSCLC)
Date and time: April 17, 2018, 8:00 AM - 12:00 PM
Location: Section 27, poster 22
Summary: CTCs collected by the Vortex technology were
characterized for their PD-L1 expression level. A PD-L1 assay was
shown to be specific, sensitive and repeatable for characterizing
CTCs. Clinical validation was performed on blood samples collected
from a cohort of 3 metastatic NSCLC patients with known PD-L1 tumor
status. Preliminary data on patients show heterogeneity in PD-L1
expression levels within a patient. While further work is required,
this poster outlines a path forward for a simple, non-invasive
method to help identify patients most likely to respond to
PD-1/PD-L1 immunotherapies.
List of presenters/authors available online here.
CTCs, shed by tumors, offer direct access to the intact cancer
biology of the patient. The fully automated, easy to use VTX-1
Liquid Biopsy System represents the next step and a valuable tool
in CTC isolation. Inside the VTX-1 chip, unlabeled CTCs in whole
blood are selectively trapped while red and white blood cells pass
through. Trapped CTCs are then released and collected for
downstream analysis. With excellent recovery of intact, viable
CTCs, high CTC purity, a low cost per run and a simple, easy to use
workflow, the VTX-1 empowers researchers and clinicians to unleash
the potential of CTCs. The posters presented at AACR 2018 take
advantage of the powerful VTX-1 system to characterize the cancer
biology of the patient by detecting well established biomarkers on
isolated CTCs.
In previous studies, the VTX-1 system has demonstrated an
ability to collect undamaged, intact CTCs with high efficiency and
high purity. The posters presented at AACR 2018 are intended to go
beyond CTC isolation to characterize the CTCs for the presence of
well understood clinical biomarkers.
About Vortex Biosciences
Vortex Biosciences is a leader in liquid biopsy solutions with a
mission to revolutionize cancer diagnosis, monitoring and treatment
by replacing tissue biopsies with simple blood tests. As a first
step in achieving this mission, they have introduced the VTX-1
Liquid Biopsy System. The VTX-1 instrument harvests intact
circulating tumor cells from whole blood samples for use in
downstream research and clinical applications such as patient
stratification, monitoring disease progression and drug treatment
effectiveness. Vortex is a core subsidiary of NetScientific plc, a
transatlantic healthcare technology group with an investment
strategy focused on sourcing, funding and commercializing
technologies that significantly improve the health and well-being
of people with chronic diseases. For more information, visit
www.vortexbiosciences.com.
# # #
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAFKNDPQBKDCQD
(END) Dow Jones Newswires
April 16, 2018 02:25 ET (06:25 GMT)
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Set 2024 até Out 2024
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Out 2023 até Out 2024